Tags

Healthcare

  • EMA Race to the Finish

    This Brexit sweepstake ensures a hardy field of expectant contenders for one of Europe’s prized agencies. It remains a hard bet to place. If we assume good old politics will work its magic, the best team will not necessarily win. As we near the home stretch, will it be the seasoned work horse dominating the…

  • The FTI Consulting Brexit Healthcare Checklist

    Love it or hate it, there’s no way to avoid Brexit – and with the vote to decide the new location of the European Medicines Agency (EMA) around the corner, there will be significant challenges ahead for business, patient welfare and the broader healthcare sector in Europe. Are you ready for the big Brexit EMA…

  • U.S. Election Results: Our Day-After Analysis

    After one of the longest, most volatile, and arguably most contentious presidential campaigns in modern American history, FTI Consulting developed detailed Day-After Analysis Reports regarding the U.S. election, providing an overview of the new balance of power and insights into the first 100 days of new leadership: U.S. Election Analysis; The First 100 Days &…

  • mHealth’s time is now!

    “It’s time to seize the potential of mHealth”. This was the clear message of yesterday’s hearing on mHealth in the European Parliament. Commissioner Andriukaitis, Members of the European Parliament Peterle and Boni and participants all agreed that mHealth, and in particular health apps, have the power to transform the relationship between patients and doctors. Speakers…

  • Meeting the challenges of patents, innovation and access to global health

    Over the past years, and as a response to the financial crisis in Europe, the pharmaceutical sector has felt the squeeze of cuts in healthcare spending. Not only have pharmaceutical companies had to re-adjust to the new market conditions, they have also been under the close scrutiny of the European Commission amidst claims of excessive…

  • Medical Device Directive: state of play and future challenges

    The European Institutions have been working on the Directive on Medical Devices and In-Vitro Diagnostics since 2012. With the adoption of the European Parliament’s position in 2013 and the Council agreeing their approach in October 2015, the process has undoubtedly been slow. It was originally hoped that a conclusion would be finally reached by Christmas…

  • Our office is growing!

    It’s been an exciting start to the year here in Brussels with the addition of seven new team members to strengthen our Competition, Trade and Financial Services practices. The additions include senior professionals from within the European Commission including Massimo Baldinato, John Clancy, Kyra Obolensky and Roeland Van der Stappen as Senior Directors, Robrecht Vandormael…

  • HTA cooperation at EU level: From “agreeing on to doing”, from therapeutic added value to cost effectiveness

    The heated debate over price transparency before the Christmas break distracted us from another important development which, being often perceived as too technical and theoretical, may in fact result in significant changes for the pharmaceutical industry: EU level cooperation on Health Technology Assessments (HTA) – the method for assessing the ways science & technology are…

  • Can high-priced medicines constitute an abuse of a dominant position in the EU?

    The price of medicines has inevitably always been, and is likely to remain, a long-standing matter of contention between originator companies, governments and patients. It has however become more acute since the launch of some very innovative but very highly priced medicines in recent months, says FTI Consulting’s Darren Kinsella.   Never mind that these…

Back to top